Filgrastim - MenoGenix

Drug Profile

Filgrastim - MenoGenix

Alternative Names: MNGX-100

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MenoGeniX
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Menopausal syndrome

Most Recent Events

  • 03 May 2018 Filgrastim is still in phase I trial for Menopausal syndrome in USA
  • 03 May 2018 MenoGeniX receives SBIR grant from National Institute on Aging (NIA) for Filgrastim development in Menopausal syndrome
  • 03 May 2018 Efficacy data from a phase I trial in Menopausal-syndrome released by MenoGeniX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top